KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Current Investments (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Cash & Current Investments data on record, last reported at $155.0 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 100.4% year-over-year to $155.0 million; the TTM value through Dec 2025 reached $155.0 million, up 100.4%, while the annual FY2025 figure was $155.0 million, 100.4% up from the prior year.
  • Cash & Current Investments reached $155.0 million in Q4 2025 per RIGL's latest filing, up from $137.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $155.0 million in Q4 2025 and bottomed at $39.3 million in Q1 2021.
  • Average Cash & Current Investments over 5 years is $87.7 million, with a median of $77.2 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: tumbled 58.98% in 2021, then surged 173.27% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $125.0 million in 2021, then crashed by 53.42% to $58.2 million in 2022, then fell by 2.19% to $56.9 million in 2023, then surged by 35.81% to $77.3 million in 2024, then skyrocketed by 100.4% to $155.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $155.0 million in Q4 2025, $137.1 million in Q3 2025, and $108.4 million in Q2 2025.